Advertisement
Screener

NASDAQ:CTOR | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | CITIUS ONCOLOGY, INC.

0.1 / 5 stars · 3/120 Roast Me

CITIUS ONCOLOGY, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect

Financial Statements › Cash Flow

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14

  • CITIUS ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-12-31 was $3.37M.
  • CITIUS ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $3.92M, a 3504182.14% increase from fiscal 2024.
  • CITIUS ONCOLOGY, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $112.00.
Period endCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 monthCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 monthCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 monthCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month
2026-06-30$12.64M
10-Q · filed 2026-08-14
2026-03-31-$1.29M
10-Q · filed 2026-05-15
2025-12-31$3.37M
10-Q · filed 2026-02-13
2025-09-30$3.92M
10-K · filed 2025-12-23
2024-09-30$112.00
10-K · filed 2025-12-23